track record that supports each element of the strategy. NLV-III will be invested in a diversified portfolio across four sectors: a primary focus on Biopharmaceuticals and Information Convergence, and a secondary focus on Medical Devices and Biological Research Tools & Infrastructure. The Fund Managers believe that